What the states have done on peptides

Federal law decides which bulk ingredients a pharmacy may compound from. States license the pharmacies, the doctors and nurses, and the clinics, and they inspect them. FDA's own presentation to its advisory committee in July 2026 said compounded products "under 503A are primarily overseen by state regulators". That makes state boards, not FDA, the regulator most clinics and pharmacies deal with day to day. This page sets out the state actions we could verify from the state's own documents.

Louisiana: peptides written into state law

Louisiana's SB 253, by Sen. Patrick McMath with Representatives Bayham, Berault, Carver and Wyble, became Act 374 of the 2026 Regular Session. It adds section 37:23.5 to the state's revised statutes, headed "Peptides; prohibited regulations". In its enacted form it says that no professional or occupational licensing board "shall prohibit a healthcare provider with prescriptive authority from providing patients with peptides" shipped from either an FDA-registered 503B outsourcing facility "in compliance with 21 U.S.C. 353b", or a 503A pharmacy in compliance with 21 U.S.C. 353a and applicable USP chapters. A second part protects a Louisiana-licensed pharmacist compounding and dispensing peptides on the same compliance condition.

The bill changed on the way. The engrossed Senate version said the prescriber "shall ensure any peptides prescribed pursuant to this Section are not on the FDA's prohibited compounding list" and referred to the "FDA Category 2 list". The enacted text instead ties everything to compliance with the federal compounding statutes. In practice that means the law cannot authorise what federal law does not: a 503A pharmacy is in compliance with section 353a only if its bulk ingredient qualifies under one of the three federal routes explained on the 503A page. What the Act does is stop Louisiana's own boards adding restrictions on top.

Ohio: research-use-only products

The Ohio Board of Pharmacy's guidance for prescriber clinics and med spas, updated 8 December 2025, is the most direct state statement we found on "research" peptides. It says no clinic "should order, possess, or administer any drugs labeled 'for research purposes only'" and that any such medication "is unlawful to possess by prescriber clinics and med spas and is both a violation of state and federal law, regardless if the patient 'consents.'" It names retatrutide and cagrilintide as examples its inspectors found, along with research-labelled semaglutide and tirzepatide. Such products, it says, "must be disposed of immediately and patients advised to discontinue" them.

The same document bars buying drugs through Facebook and other social media, from unlicensed internet sellers, or from other clinics. It says the Board summarily suspended more than 30 clinics and med spas after finding "clear and convincing evidence they pose a danger of immediate and serious harm to others". Citations are published on the Board's website.

Texas: wellness IV clinics

Texas's H.B. 3749, known as Jenifer's Law, followed the death of a woman after an IV infusion at a spa in 2023. It adds a chapter to the Occupations Code on elective intravenous therapy: treatment a patient seeks for temporary discomfort or wellness, given outside a physician's office or licensed facility. The law requires a physician's order, or delegation to a physician assistant or advanced practice registered nurse, and ends delegation to unlicensed staff. It does not mention peptides, but many clinics offering IV hydration also offer injectable peptides, and the same clinics fall under it.

What we could not verify

Several online guides describe peptide-specific rules in other states, including pending Florida bills and Texas pharmacy board requirements. We could not confirm them from a legislature or board website, so they are not listed here. State medical and pharmacy boards also act case by case through discipline, which is published but not collected in one place. If you run a clinic or pharmacy, your state board's own guidance is the authority, not this page.

How state and federal rules fit together

• Which ingredient: federal. The 503A list, USP monographs and approved-drug components decide what may be compounded.
• Who may prescribe, compound, administer: state licensing law and boards.
• Where products are bought: both. Ohio's rule against research-labelled drugs sits alongside FDA warning letters to the sellers (see enforcement).
• What a state cannot do: make a substance lawful to compound under federal law. Louisiana's Act ties its protection to federal compliance for this reason.

For federal context, see the timeline and the Category 2 status table.

Rules change faster than most people's records. If you are on a prescribed peptide, the dose log keeps each dose with the product, the pharmacy and the concentration, and bloodwork sits on the same timeline, so a change of product or source is easier to plan with your prescriber. The peptide library grades how much research exists behind each compound, and that grading does not move when a committee votes. The app is on iOS and Android.